The rising prevalence of chronic diseases such as cancer and autoimmune diseases has increased the demand for biologics drugs globally. Antibody drug conjugates (ADCs) are biopharmaceutical drugs that combine monoclonal antibodies with cytotoxic agents used mainly for targeted drug delivery in the treatment of various cancer types. ADC contract manufacturing involves the development and manufacturing of ADC drug molecules outsourced to contract development and manufacturing organizations (CDMOs) by biopharmaceutical companies. CDMOs offer integrated services of antibody engineering, linker payload design, process development, and manufacturing of drug substance and drug product under cGMP guidelines.
The Global ADC Contract Manufacturing Market is estimated to be valued at USD 1.83 Billion in 2024 and is expected to reach USD 4.30 Billion by 2031, growing at a compound annual growth rate (CAGR) of 13.2% from 2024 to 2031.
Key players operating in the ADC contract manufacturing market are Lonza, Catalent Inc., FUJIFILM Diosynth Biotechnologies, Syngene Biopharma Ltd., KBI Biopharma Inc. etc. These players are engaged in expanding their ADC contract manufacturing capabilities to cater to the increasing demand.
The key opportunities in the ADC Contract Manufacturing Market include the increasing demand for ADC drugs from biopharma companies and the growing ADCs pipeline. More than 70 ADCs are in clinical trials which indicates significant growth opportunities. The major players are expanding their geographic presence globally through new facility investments and acquisitions. For instance, Lonza launched its large-scale antibody-drug conjugate (ADC) manufacturing facility in Singapore in 2020 to service the Asia-Pacific region.
Market Drivers
The increasing adoption of ADC therapies especially for cancer treatment is driving the growth of the ADC contract manufacturing market. Biopharma companies are outsourcing ADC development and manufacturing to CDMOs to reduce costs and fast-track their ADC pipeline.
Market Restraints
High costs associated with ADC development, manufacturing and supply chain challenges are the major restraints for the market. ADC production involves complex conjugate synthesis and analytical characterization which increases manufacturing costs. Supply shortages of raw materials can also hamper market growth.
Segment Analysis
The ADC Contract Manufacturing market can be segmented into Commercial manufacturing and clinical manufacturing based on application. Commercial manufacturing accounts for over 60% of market share and is dominant due to steady demand for biosimilars/biobetters drugs requiring mass production. Antibody-drug conjugates for oncology applications dominates commercial segment attribute to fast regulatory approvals and established production infrastructure for oncology drugs.
Regional Analysis
North America accounts for over 40% market share dominating global ADC Contract Manufacturing market. Presence of majority bio-pharmaceutical vendors and favorable regulatory environment support market growth. Availability of capital and advanced production facilities for biologics manufacturing accelerate regional clinical activity. Asia Pacific projected to grow with highest CAGR during forecast period. Expanding biologics production units of global pharma companies and emerging regional biosimilars industry strengthen regional outsourcing. Additionally contract manufacturing sees adoption to curtail in-house production costs.
Get this Report in Japanese Language: ADC受託製造市場
Get this Report in Korean Language: ADC 계약 제조 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
